July 15, 2019—Abbott announced FDA approval for its blood and plasma screening instrument, the Alinity s System.
Features of the system include the capacity to run up to 600 tests per hour, a minimum three-hour walkaway time, the ability to continuously load and unload samples and supplies, and an intuitive software interface, menu design, and sample loading layout.
“In order to ensure a safe blood and plasma supply, we need access to the most advanced technologies to screen donations,” Rachel-Louise Beddard, MD, senior vice president and chief medical officer, QualTex Laboratories, said in an Abbott press release. “Alinity s will help us transform the way we conduct screening, so we can do our jobs most efficiently, allowing us to get the life-saving blood and plasma products to people facing their most critical situations.”